Fujita Health University's Groundbreaking Discovery in Cancer Research

Researchers at Fujita Health University in Japan have uncovered a critical mechanism explaining why cancer immunotherapy often falls short in treating patients. This advance centers on how tumors deploy small extracellular vesicles (sEVs), tiny bubble-like structures released by cancer cells, to shuttle the immunosuppressive protein PD-L1 (Programmed Death-Ligand 1) throughout the body. PD-L1 binds to PD-1 receptors on T cells, essentially putting the brakes on the immune system's attack against tumors. By packaging PD-L1 into sEVs, cancer cells create a widespread shield, evading checkpoint inhibitors like anti-PD-1 or anti-PD-L1 antibodies that only work locally.

The study, published in December 2025 in Scientific Reports, reveals that this sorting process depends on a unique modification by the protein UBL3 (ubiquitin-like protein 3). UBL3 attaches to PD-L1 at cysteine 272 via a disulfide bond—a non-traditional posttranslational tweak that signals PD-L1 for encapsulation into sEVs without altering its total cellular levels. This insight not only demystifies immune evasion but points to an unexpected ally: statins, the widely used cholesterol-lowering drugs.

Understanding Cancer Immunotherapy and Its Limitations

Cancer immunotherapy harnesses the body's own immune system to target and destroy malignant cells, marking a paradigm shift from traditional chemotherapy and radiation. Immune checkpoint inhibitors, which block the PD-1/PD-L1 axis, have revolutionized treatment for cancers like non-small cell lung cancer (NSCLC), melanoma, and others. However, their success rate hovers around 20-25% in many cases, leaving clinicians searching for reasons behind primary or acquired resistance.

One underappreciated factor is the role of sEVs, nanoscale vesicles (30-150 nm) shed by tumor cells into the bloodstream and tumor microenvironment. These carriers transport bioactive molecules, including PD-L1, to distant sites, systemically dampening T-cell activity. Elevated PD-L1-positive sEVs in patient serum correlate with poorer responses to therapy, but the 'how' of selective loading remained elusive until now.

Spotlight on Fujita Health University: A Hub for Medical Innovation in Japan

Established in 1964 in Toyoake, Aichi Prefecture, Fujita Health University (FHU) stands as a premier private institution dedicated to health sciences. Comprising medical, nursing, and rehabilitation faculties, FHU emphasizes team-based medical care and cutting-edge research through its Center for Medical Science. The university has garnered recognition, ranking 11th among Japanese universities and first among privates in the 2018 Times Higher Education Japan University Rankings for clinical and health fields.

FHU's Division for Therapies Against Intractable Diseases, where this study originated, focuses on unraveling complex diseases like cancer. Led by Professor Kunihiro Tsuchida, the team collaborated with Tokyo Medical University, blending expertise in molecular biology, bioinformatics, and clinical sampling. This work exemplifies Japan's robust higher education ecosystem, where universities like FHU drive global biomedical advances. For aspiring researchers, opportunities abound in research jobs at such institutions, fostering careers in oncology and immunology.

The Novel UBL3-PD-L1 Pathway: Step-by-Step Breakdown

The discovery hinges on UBL3's role in modifying PD-L1. Here's how it unfolds:

• Cancer cells express PD-L1 on their surface and internally.
• UBL3 binds to PD-L1's cytoplasmic tail at cysteine 272, forming a disulfide bond.
• This modification flags PD-L1 for multivesicular body (MVB) incorporation.
• MVBs fuse with the plasma membrane, releasing PD-L1-laden sEVs.
• Circulating sEVs bind PD-1 on distant T cells, suppressing antitumor immunity.

Experiments confirmed this: Overexpressing UBL3 boosted sEV PD-L1 without raising total PD-L1; knockdown did the opposite. Bioinformatics linked high UBL3/PD-L1 expression to worse lung cancer survival.

Photo by YEH CHE WEI on Unsplash

Statins Enter the Stage: Repurposing for Immunotherapy Enhancement

Statins—atova, simva, rosuva, prava, fluva—universally inhibited UBL3 modification at low doses (1-10 μM), slashing PD-L1 sEV levels by 50-80% in cell lines without cytotoxicity. Mechanistically, statins disrupt geranylgeranylation, a lipid modification needed for UBL3 function, indirectly blocking the pathway.

In a retrospective analysis of NSCLC patients with high tumor PD-L1 (TPS ≥50%), statin users showed markedly lower serum PD-L1 sEVs versus non-users, hinting at real-world benefits. Prior studies echo this: Statin co-use improved outcomes in ICI-treated lung cancer patients.

Read the full study here.

Clinical Evidence and Broader Implications

Patient cohorts from Tokyo Medical University Hospital validated the lab findings. High TPS patients on statins had reduced circulating suppressors, potentially explaining better ICI responses observed elsewhere. Statins' safety profile—billions of prescriptions yearly—makes them ideal adjuncts: inexpensive, oral, low-risk.

Implications ripple across oncology: For PD-L1-high tumors resistant to monotherapy, statin combos could expand the 25% responder pool. Trials like NCT05636592 explore statin+ICI in NSCLC.

This aligns with Japan's push in precision medicine, where FHU contributes to national cancer moonshots.

Challenges and Future Directions in Research

While promising, hurdles remain: Optimal statin dosing/timing with ICIs needs prospective trials. sEV heterogeneity across cancers varies; lung-focused data may not generalize to breast or prostate tumors. Biomarker development—UBL3 expression or sEV PD-L1 levels—could stratify patients.

• Phase II/III trials combining statins with pembrolizumab/nivolumab.
• UBL3 inhibitors as novel targeted agents.
• sEV engineering for drug delivery counter-strategies.

FHU's work paves the way; check postdoc positions for involvement.

Career Opportunities in Japan's Medical Research Landscape

This breakthrough underscores Japan's allure for biomedical careers. FHU and peers like Tokyo Medical University offer research assistant jobs, faculty roles, and postdocs. With rising international collaborations, English-proficient researchers thrive. Tailor your CV with tips from our academic CV guide.

Japan's universities prioritize innovation; explore Japan higher ed jobs amid immunotherapy booms.

Photo by Stephen Boss on Unsplash

Global Impact and Patient Hope

Beyond Japan, this could democratize immunotherapy. Statins, generic and accessible, bridge gaps in low-resource settings. FHU's contribution elevates Japanese higher ed's profile, attracting global talent via university jobs.

Stakeholders—patients, oncologists, researchers—gain actionable insights. Monitor for guidelines updates incorporating statins.

Professor Tsuchida notes: "This may lead to more effective, accessible therapies."

Conclusion: A New Era for Cancer Treatment

Fujita Health University's revelation of the UBL3-PD-L1-sEV axis, countered by statins, heralds enhanced immunotherapy. Aspiring professionals, dive into rate my professor for insights, seek higher ed jobs, and arm with career advice. FHU exemplifies research excellence driving real change.